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Identifying the tests/procedures ordered by neurologists
that contribute most to health care expenditures is a
critical step in the process of creating the neurology top
5 list for the Choosing Wisely initiative. Using data from
the 2007–2010 National Ambulatory Care Medical Sur-
vey, we found that $13.3 billion (95% confidence inter-
val5 $10.1–$16.5 billion) was spent on tests ordered at
neurologist visits. The tests/procedures with the highest
expenditures were magnetic resonance imaging (MRI;
51% of total expenditures; $7.5 billion), electromyogra-
phy (EMG; 20% of expenditures; $2.6 billion), and elec-
troencephalography (EEG; 8% of expenditures; $1.1
billion). MRI, EMG, and EEG should receive close scru-
tiny in the development of the neurology top 5 list.
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In response to unsustainable growth in health careexpenditures,1 the American Board of Internal Medi-
cine launched the Choosing Wisely initiative.2,3 As part
of this initiative, medical professional societies have been
encouraged to identify 5 non–value-added tests or proce-
dures commonly used in their field, whose necessity
should be carefully scrutinized. One potential virtue of
this approach is that by identifying and decreasing the
use of low-value tests/procedures, physicians demonstrate
to a skeptical public that they are genuinely protecting
patients’ interests rather than rationing health care.3
So far, 9 specialty societies have each developed a top
5 list. Examples of list items include: “Don’t obtain imaging
studies in patients with non-specific low back pain” and
“In the evaluation of simple syncope and a normal neuro-
logical examination, don’t obtain brain imaging studies (CT
or MRI)” (American College of Physicians).4 The American
Academy of Neurology recently joined the Choosing
Wisely initiative and plans to release a top 5 list in 2013.5
A recent critique of the first of the published top 5
lists is that many of the tests/procedures had only mar-
ginal, or in some cases negligible, impact on health care
costs.6,7 As a result, it has been recommended that future
top 5 list development efforts should incorporate cost in-
formation to ensure that high-impact services are
addressed.6 In this study, we sought to define the tests
and procedures associated with the highest expenditures
in outpatient neurologic care and identify the clinical sce-
narios where those tests are most commonly used.
Patients and Methods
Data Set
The National Ambulatory Medical Care Survey (NAMCS) is a
nationally representative survey conducted annually by the Cen-
ters for Disease Control and Prevention.8 NAMCS is designed
using a 3-stage sampling design (geographic regions, physician
practices stratified within specialties, and patient visits within
practices) to enable a nationally representative characterization
of outpatient office-based care. For this study, we analyzed all
neurologist visits in NAMCS from 2007 to 2010. This sample
includes data from 125,029 visits, including 6,764 visits by 195
unique neurologists.
Diagnoses
The principal NAMCS diagnosis for each visit (using Interna-
tional Classification of Diseases, 9th Edition, Clinical Modifica-
tion [ICD-9-CM] codes) was used to categorize diagnoses with
Healthcare Cost and Utilization Project multilevel diagnosis
Clinical Classifications Software.9 For these analyses, each prin-
cipal diagnosis was categorized by the lowest level diagnostic
category in which it was classified.
Tests/Procedures
Test/procedure utilization data are abstracted onto the standar-
dized NAMCS survey instrument by provider practices either
by checking boxes for specific procedures (magnetic resonance
imaging [MRI], computed tomography [CT], x-rays, some
laboratory tests, and ultrasound studies) or by handwriting
test/procedure names in available additional space if no check-
box is available (eg, electromyography [EMG], electroencepha-
lography [EEG], polysomnography [PSG]). Handwritten tests/
procedures are later translated into ICD-9 procedure codes.
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Tests/procedures were included in this study if they appeared in
the sample 5 or more times. Laboratory tests were combined
into an index variable representing the total number of labora-
tory tests used in a given patient.
Payments
Payments were determined using the Medicare physician fee
schedule and Medicare Clinical Laboratory Fee Schedule for
tests/procedures and laboratory tests, respectively.10,11 Total pay-
ments were calculated by adding all payments for all tests/pro-
cedures. The NAMCS survey instrument does not capture what
portion of the body was imaged for CT or MRI, and ICD-9-
CM procedure codes for EMG and EEG do not offer sufficient
detail to determine the average payments associated with these
procedures. Consequently, we used all Medicare claims associ-
ated with the Health and Retirement Study (HRS) popula-
tion,12 a nationally representative sample, to estimate the pay-
ments associated with the average test (eg, the average MRI or
the average EMG) ordered by a neurologist. To estimate this
average for each test, we determined the distribution of test
components performed when ordered by a neurologist. In this
way, we were able to account for variation in number of body
TABLE 1. All Principal Diagnoses for Neurologist Visits with >500,000 Visits (Classified by Most Distal Multile-
vel CCS Category) in National Ambulatory Medical Care Survey from 2007 to 2010
Diagnosis Total No. of Visits,
in Millions (95% CI)
Average No. of
Visits per Year,
in Millions (95% CI)
Disorders of the peripheral nervous system 6.03 (4.32–7.74) 1.51 (1.08–1.93)
Migraine 5.01 (3.55–6.47) 1.25 (0.89–1.62)
Other back problems 4.00 (2.42–5.57) 1.00 (0.61–1.39)
Epilepsy 3.92 (2.65–5.19) 0.98 (0.66–1.30)
Residual codes, unclassifieda 3.01 (1.55–4.46) 0.75 (0.39–1.12)
Other headache 2.62 (1.81–3.44) 0.66 (0.45–0.86)
Convulsions 2.56 (1.77–3.35) 0.64 (0.44–0.84)
Other nervous system symptoms and disordersb 2.52 (1.73–3.31) 0.63 (0.43–0.83)
Parkinson disease 2.5 (1.75–3.25) 0.62 (0.44–0.81)
Delirium, dementia, amnestic, and other
cognitive disorders
2.29 (1.59–3) 0.57 (0.40–0.75)
Multiple sclerosis 2.25 (1.34–3.17) 0.56 (0.33–0.79)
Other hereditary and degenerative
nervous system conditions
1.85 (1.35–2.35) 0.46 (0.34–0.59)
Other connective tissue disease 1.84 (1.17–2.52) 0.46 (0.29–0.63)
Acute cerebrovascular disease 1.3 (0.83–1.77) 0.33 (0.21–0.44)
Other central nervous system disorders 1.29 (0.78–1.8) 0.32 (0.16–0.45)
Intervertebral disk disorders 1.19 (0.34–2.03) 0.30 (0.09–0.51)
Conditions associated with dizziness or vertigo 1.03 (0.71–1.35) 0.26 (0.18–0.34)
Missing 0.72 (0.37–1.08) 0.18 (0.09–0.51)
Transient cerebral ischemia 0.67 (0.32–1.01) 0.17 (0.08–0.25)
Attention deficit disorder and attention deficit
hyperactivity disorder
0.62 (0.15–1.1) 0.16 (0.04–0.27)
Other aftercarec 0.56 (0.18–0.95) 0.14 (0.05–0.24)
Syncope 0.55 (0.32–0.78) 0.14 (0.08–0.20)
Spondylosis and allied disorders 0.55 (0.2–0.89) 0.14 (0.05–0.22)
aRefers to diagnoses that are not accounted for in the CCS system.
bBroad category capturing a variety of neurologic diagnoses not otherwise specifically identified.
cCaptures a list of diagnostic codes associated with posthospitalization care.
CCS5Clinical Classifications Software; CI5 confidence interval.
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segments tested and protocols. After determining the distribu-
tion of test components per average test, we applied the
national limit payment amounts for each test component sepa-
rately and summed these components to determine the pay-
ment for an average test. For comparison purposes, the total
expenditures on evaluation and management (E&M) services
were estimated using a similar approach. The proportion of
individual E&M codes used by neurologists was calculated in
the Medicare HRS population, and then the cost of the average
neurologist visit was estimated by taking a weighted average of
national limit payment amounts.
Statistical Analysis
Descriptive statistics using survey weights were used to estimate
the number of visits for each diagnosis category, total expendi-
tures for all test categories, and expenditures for all tests by
diagnostic categories. All analyses were performed in Stata ver-
sion 12.1 (StataCorp, College Station, TX).
Results
A total of 58 million (95% confidence interval
[CI]5 44–72 million) visits to the neurologist were iden-
tified from 2007 to 2010. The 3 most common diagnos-
tic categories were disorders of the peripheral nervous
system, migraine, and back pain (Table 1).
From 2007 to 2010, a total of $13.3 billion (95%
CI5 $10.1–$16.5 billion) was spent on diagnostic tests
ordered at neurologist visits, with a minimum of $3.2
billion spent in every year (Table 2). MRI accounted for
57% of all diagnostic expenditures ($7.5 billion; 95%
CI5 $5.7–$9.4 billion). EMG accounted for 20% of
expenditures ($2.6 billion; 95% CI5 $1.9–$3.3 billion)
and EEG for 8.3% ($1.1 billion; 95% CI5 $0.7–$1.5
billion). Together, EMG and EEG accounted for 64% of
the non–MRI-related expenditures. Expenditures associ-
ated with PSG increased over time, but were <5% of
total expenditures in 2010. Laboratory testing accounted
for only 1.6% of overall expenditures. By comparison, a
total of $6.1 billion (95% CI5 $4.7–$7.6 billion) was
spent on all evaluation and management services attribut-
able to neurologists over this time period.
The diagnostic category with the highest single test
expenditures was disorders of the peripheral nervous
system, with EMG costs of $820 million (95%
CI5 $520 million–$1.1 billion; Fig). The only other
diagnostic category with EMG expenditures >$250 mil-
lion was “other back problems.” The diagnostic category
of migraine had the second highest single-test expendi-
tures, with MRI costs of $690 million (95% CI5 $350
million–$1 billion). In contrast with EMG, MRI had 12
diagnostic categories with expenditures of $250 million
or more. For EEG, epilepsy was the only diagnostic
category with expenditures totaling >$200 million
(Supplementary Table). T
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Discussion
The Choosing Wisely campaign aims to reduce unsus-
tainable health care expenditures by identifying clinical
contexts in which specific tests/procedures may be waste-
ful. Identifying targets in neurology requires considera-
tion first of the net clinical utility of a given test/proce-
dure and secondarily of financial costs. In this study, we
identified the highest-cost tests/procedures in outpatient
care ordered by neurologists. Given their contributions to
overall expenditures, MRI, EMG, and EEG should
receive close scrutiny in the development of the neurol-
ogy top 5 list, as together these tests account for 84% of
all costs attributable to outpatient neurologist care.
Due to their relatively low expenditures, laboratory
tests, CT, ultrasound, and other imaging studies should
be given a lower priority in the development of the neu-
rology top 5 list. PSG expenditures may increase in im-
portance if the observed increases from 2007 to 2010
continue into the future.
The primary remaining challenge in developing a
top 5 list is to identify the specific clinical scenarios
where these tests are of sufficiently low value as to be
considered unnecessary or even wasteful.4 Items in top 5
lists are typically written to discourage the use of a spe-
cific test within a specific clinical circumstance.4 We
found that the expenditures for MRI were widely
dispersed among 12 different diagnostic categories. EMG
and EEG expenditures were more concentrated within
the diagnostic categories, although those specific catego-
ries (eg, disorders of the peripheral nervous system, epi-
lepsy) are sufficiently broad to necessitate additional steps
to identify specific clinical scenarios in which these ex-
pensive tests do not add value. Given the paucity of data
on the net clinical value of tests/procedures, research
studies designed to define the value of these tests in spe-
cific clinical scenarios are needed to ensure that waste
reduction efforts can be based on evidence.
Other strategies are being used to address test/pro-
cedure-related expenditures such as recently implemented
coding and payment changes for EMG/nerve conduction
studies. The impact of such across-the-board cuts on
expenditures remains to be determined. Given the mag-
nitude of expenditure difference between MRI, EMG,
EEG, and other tests, however, the relative expenditure
rankings of these tests is unlikely to change unless there
is a substantial decline in expenditures for 1 test. If such
broad reimbursement changes do reduce overall expendi-
tures, they may not do so in a way that targets actual
waste while preserving value, which is the aim of more
focused expenditure-reduction efforts, such as the Choos-
ing Wisely campaign.13,14
This study is limited by the available data from the
NAMCS data set and the estimates of payments available.
These data include little detail on the specifics of tests that
were ordered, and thus we standardized costs to the cost
of an average test (eg, the average MRI or average EMG
FIGURE : Estimated payments for the 5 most costly tests for the 10 most common diagnostic categories. CT5 computed to-
mography; EEG5electroencephalography; EMG5electromyography; MRI5magnetic resonance imaging; PSG5polysomnog-
raphy; USD5US dollars. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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ordered by neurologists). This approach should lead to
unbiased and conservative (by failing to account for higher
payments paid by private insurers) estimates of overall
payments, but may introduce some bias for specific clini-
cal scenarios where a more or less expensive version of a
test is used compared to the average. Finally, NAMCS
offers limited clinical detail on the circumstances sur-
rounding why specific tests were ordered, limiting infer-
ences about the value of the tests/procedures identified
here. Without such details, we cannot conclude that any
test or procedure is overused; nor can we exclude the pos-
sibility of underutilization in appropriate clinical contexts.
Rather, these data simply establish which tests/procedures
account for the most resources.
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